CN103717239B - 适合于吸入的氧化抗生物素蛋白的药物组合物 - Google Patents
适合于吸入的氧化抗生物素蛋白的药物组合物 Download PDFInfo
- Publication number
- CN103717239B CN103717239B CN201280037217.9A CN201280037217A CN103717239B CN 103717239 B CN103717239 B CN 103717239B CN 201280037217 A CN201280037217 A CN 201280037217A CN 103717239 B CN103717239 B CN 103717239B
- Authority
- CN
- China
- Prior art keywords
- biotinylation
- oxavidin
- lung
- avidin
- oxidized avidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11006338 | 2011-08-02 | ||
| EP11006338.5 | 2011-08-02 | ||
| PCT/EP2012/064576 WO2013017494A1 (en) | 2011-08-02 | 2012-07-25 | Pharmaceutical composition of oxidised avidin suitable for inhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103717239A CN103717239A (zh) | 2014-04-09 |
| CN103717239B true CN103717239B (zh) | 2017-08-01 |
Family
ID=46581966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280037217.9A Active CN103717239B (zh) | 2011-08-02 | 2012-07-25 | 适合于吸入的氧化抗生物素蛋白的药物组合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9872831B2 (enExample) |
| EP (1) | EP2739314B1 (enExample) |
| JP (1) | JP6019118B2 (enExample) |
| KR (1) | KR101966630B1 (enExample) |
| CN (1) | CN103717239B (enExample) |
| AU (1) | AU2012292229B2 (enExample) |
| BR (1) | BR112014002593B1 (enExample) |
| CA (1) | CA2842276C (enExample) |
| DK (1) | DK2739314T3 (enExample) |
| EA (1) | EA026453B1 (enExample) |
| ES (1) | ES2729549T3 (enExample) |
| IL (1) | IL230597A0 (enExample) |
| MX (1) | MX355177B (enExample) |
| PH (1) | PH12014500193A1 (enExample) |
| PL (1) | PL2739314T3 (enExample) |
| PT (1) | PT2739314T (enExample) |
| UA (1) | UA114482C2 (enExample) |
| WO (1) | WO2013017494A1 (enExample) |
| ZA (1) | ZA201401921B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016511747A (ja) | 2013-01-04 | 2016-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | ナノ粒子表面結合に基づく薬物の組織への送達 |
| WO2017201436A1 (en) * | 2016-05-19 | 2017-11-23 | University Of Miami | Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2106806A1 (en) * | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
| CN101772353A (zh) * | 2007-08-02 | 2010-07-07 | 希格马托制药工业公司 | 在受治疗组织中展现高停留时间的氧化的抗生物素蛋白 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5384128A (en) * | 1993-03-02 | 1995-01-24 | University Of Alabama Research Foundation | Method of and compounds for treatment for cystic fibrosis |
| NZ271181A (en) | 1993-07-19 | 1998-06-26 | Amgen Inc | Protein protection; method for stabilising aerosolised proteins by adding a water-soluble polar organic compound to the aqueous solution prior to aerosolisation |
| NZ337924A (en) * | 1997-02-20 | 2002-09-27 | Klaus Kimmeldirk | Site-specific drug delivery compounds comprising an anchoring moiety, a linking group and a drug |
| AU779869B2 (en) * | 1999-04-13 | 2005-02-17 | Nektar Therapeutics | Pulmonary administration of dry powder formulations for treating infertility |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| EP2311793A1 (en) * | 2004-12-17 | 2011-04-20 | Cipla Ltd. | Crystalline levosalbutamol sulphate (Form II) |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| TW201031436A (en) * | 2009-02-16 | 2010-09-01 | Univ Nat Taiwan | Pharmaceutical composition for inhalation delivery and fabrication method thereof |
-
2012
- 2012-07-25 PH PH1/2014/500193A patent/PH12014500193A1/en unknown
- 2012-07-25 DK DK12740137.0T patent/DK2739314T3/da active
- 2012-07-25 ES ES12740137T patent/ES2729549T3/es active Active
- 2012-07-25 EP EP12740137.0A patent/EP2739314B1/en active Active
- 2012-07-25 PL PL12740137T patent/PL2739314T3/pl unknown
- 2012-07-25 KR KR1020147001707A patent/KR101966630B1/ko not_active Expired - Fee Related
- 2012-07-25 US US14/236,445 patent/US9872831B2/en active Active
- 2012-07-25 JP JP2014523289A patent/JP6019118B2/ja active Active
- 2012-07-25 PT PT12740137T patent/PT2739314T/pt unknown
- 2012-07-25 EA EA201490401A patent/EA026453B1/ru not_active IP Right Cessation
- 2012-07-25 MX MX2014001176A patent/MX355177B/es active IP Right Grant
- 2012-07-25 AU AU2012292229A patent/AU2012292229B2/en not_active Ceased
- 2012-07-25 WO PCT/EP2012/064576 patent/WO2013017494A1/en not_active Ceased
- 2012-07-25 CA CA2842276A patent/CA2842276C/en active Active
- 2012-07-25 BR BR112014002593-2A patent/BR112014002593B1/pt not_active IP Right Cessation
- 2012-07-25 UA UAA201402021A patent/UA114482C2/uk unknown
- 2012-07-25 CN CN201280037217.9A patent/CN103717239B/zh active Active
-
2014
- 2014-01-22 IL IL230597A patent/IL230597A0/en active IP Right Grant
- 2014-02-27 ZA ZA2014/01921A patent/ZA201401921B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101772353A (zh) * | 2007-08-02 | 2010-07-07 | 希格马托制药工业公司 | 在受治疗组织中展现高停留时间的氧化的抗生物素蛋白 |
| EP2106806A1 (en) * | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
Non-Patent Citations (1)
| Title |
|---|
| Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step;Otto C. Boerman et al.;《The Journal of Nuclear Medicine》;20030331;第44卷(第3期);第400-411页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014002593A2 (pt) | 2017-03-01 |
| KR20140047668A (ko) | 2014-04-22 |
| BR112014002593B1 (pt) | 2022-11-29 |
| ES2729549T3 (es) | 2019-11-04 |
| CN103717239A (zh) | 2014-04-09 |
| PH12014500193A1 (en) | 2014-03-24 |
| UA114482C2 (uk) | 2017-06-26 |
| EP2739314A1 (en) | 2014-06-11 |
| DK2739314T3 (da) | 2019-06-24 |
| CA2842276C (en) | 2020-11-24 |
| MX2014001176A (es) | 2014-07-14 |
| EA201490401A1 (ru) | 2014-05-30 |
| JP2014521675A (ja) | 2014-08-28 |
| MX355177B (es) | 2018-04-09 |
| KR101966630B1 (ko) | 2019-04-09 |
| AU2012292229B2 (en) | 2017-08-03 |
| ZA201401921B (en) | 2015-05-27 |
| PL2739314T3 (pl) | 2019-09-30 |
| PT2739314T (pt) | 2019-06-21 |
| JP6019118B2 (ja) | 2016-11-02 |
| NZ620202A (en) | 2016-05-27 |
| WO2013017494A1 (en) | 2013-02-07 |
| EA026453B1 (ru) | 2017-04-28 |
| CA2842276A1 (en) | 2013-02-07 |
| AU2012292229A1 (en) | 2014-02-13 |
| US20140134106A1 (en) | 2014-05-15 |
| IL230597A0 (en) | 2014-03-31 |
| US9872831B2 (en) | 2018-01-23 |
| EP2739314B1 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070231408A1 (en) | Colloidal metal compositions and methods | |
| US20110064652A1 (en) | Nanoparticles for targeted delivery of active agents to the lung | |
| CN117924503A (zh) | 人源化抗前列腺特异性膜抗原(psma)抗体药物缀合物 | |
| CN111954531A (zh) | α聚谷氨酸化培美曲塞及其用途 | |
| Maillet et al. | The airways, a novel route for delivering monoclonal antibodies to treat lung tumors | |
| CN111954529A (zh) | α聚谷氨酸化氨甲蝶呤及其用途 | |
| CN111936146A (zh) | α聚谷氨酸化四氢叶酸及其用途 | |
| RS60181B1 (sr) | Terapeutska upotreba morfogenetskih proteina kosti | |
| Aggarwal et al. | Pulmonary fibrosis: Unveiling the pathogenesis, exploring therapeutic targets, and advancements in drug delivery strategies | |
| CN118766874B (zh) | 一种吸入式制剂、迭代优化流程及其应用 | |
| EP2739314B1 (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| JP2001512831A (ja) | 生物学的薬剤組成物を同定する方法 | |
| JPWO2020071448A1 (ja) | 吸入粉末剤、その評価方法及びその用途 | |
| HK1194002A (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| HK1194002B (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| NZ620202B2 (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| US10912791B2 (en) | Compositions comprising antisense-encoded erythropoietin receptor and use thereof | |
| EP4188433A2 (en) | Targeted delivery of therapeutic agents | |
| Song et al. | In situ needle-free injection of multiretention micelles for melanoma therapy with multiomics insights into tumor targeting and immune modulation | |
| Zarogoulidis et al. | Airway local endoscopic pharmacological treatment; current applications and future concepts | |
| US20180177724A1 (en) | Site-targeted nano-liposomal nitroglycerin therapeutics | |
| KR20260043572A (ko) | 폐암 치료를 위한 페메트렉시드-기능화 종양 미세환경 표적 흡입용 약물전달시스템 | |
| Li | Development of an Aerosol-Based Immunotherapy for Non-Small Cell Lung Cancer | |
| Huayamares et al. | Current Research in Biotechnology | |
| Gaber et al. | In vivo pharmacodynamics of lactoferrin-coupled lipid nanocarriers for lung carcinoma: intravenous versus powder for inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194002 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180118 Address after: Milan Italy Patentee after: Alpha Sigmar joint-stock company Address before: Rome Italy Patentee before: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Bologna, Italy Patentee after: Alpha sigma Co., Ltd Address before: Milan Italy Patentee before: Alpha Sigmar JSC |